The DOI matches its Crossref record.
Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
Abstract
Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994:130: 494–7. ISSN 0804–4643 The roles of thyroid hormones and thryotropin (TSH) in the development of Graves' ophthalmopathy are not clear. Some studies suggest a protective effect of thyroid hormones on experimental exophthalmos and an adverse effect of increased TSH levels. In September 1988 we introduced early thyroxine (T 4) administration after 131 I therapy for hyperthyroidism caused by Graves' disease. We carried out a retrospective study of records from all patients with this disease treated with 131 I for 4 years. During the first 2 years 248 patients were treated (group A). They received T 4 when the serum concentration of TSH and/or T 4 indicated hypothyroidism. During the next 2 years 244 patients were treated (group B). They were all given 0.05 mg of T 4 daily, starting 2 weeks after therapy, and 0.1 mg after a further 2 weeks. With a follow-up of 18 months, 45 patients (18%) in group A and 27 patients (11%) in group B developed or deteriorated in an already present ophthalmopathy (p = 0.03, relative risk = 1.64, 95% confidence interval = 1.05–2.55). Twenty-six patients in group A required specific therapy for the ophthalmopathy (e.g. antithyroid drugs, steroids, etc.) compared to 11 patients in group B (p = 0.02, relative risk = 2.33; 95% confidence interval = 1.18–4.60). Our results suggest that early administration of T 4 after 131 I therapy reduces the occurrence of Graves' ophthalmopathy. L Tallstedt, Department of Ophthalmology, Huddinge University Hospital, S-146 81 Huddinge, Sweden
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“for GO are listed in Table 15, and the most pertinent ones to this discussion are RAI therapy for hyperthyroidism (531,532), untreated hyperthyroidism, smoking, high serum pretreatment TRAb levels (normal <1.75 IU/L, high risk for progression if >8.8 IU/L) (533), and any delay in treating hypothyroidism after therapy for hyperthyroidism (106,534).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [534]
In the citing paper
“Subsequently, two cohort studies in which patients received levothyroxine therapy early after RAI with the specific intent of preventing hypothyroidism noted that deterioration of GO rarely occurred (0%-2%) (534,536).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [534]
In the citing paper
“High pretreatment levels of T 3 and T 4 were each reported to have a predictive role in GO, but these conclusions were not validated by subsequent studies (69,106,532,534), suggesting the possibility of higher TRAb values measured on less sensitive assays early-on being partly responsible for this variation.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [534]
Citations
Cited by
Sorted by citations
Items 101–172 of 172
Radioiodine Therapy and Graves' Ophthalmopathy
Spitzweg, C., Rossmüller, B., & Heufelder Armin, E. (1998) · Thyroid · doi:10.1089/thy.1998.8.1193 · Cited by 9
“In a retrospective evaluation ( 20 ) and a prospective study (3), prolonged hypothyroidism was significantly associated with progressive ocular changes; these reports led to preventive or prompt treatment of hypothyroidism by others (2,4,6).”
Update on the medical treatment of Graves’ ophthalmopathy
Garrity, J. (2009) · International Journal of General Medicine · doi:10.2147/ijgm.s6856 · Cited by 8
“This risk may be mitigated with a short course (3 months) of oral glucocorticoids (GCs),(34) along with avoidance of post-operative hypothyroidism.(35) Patients with risk factors such as smoking along with greater than mild GO are most likely to benefit from pretreatment.”
Thyrostimulin (a TSH-like Hormone) Expression in Orbital and Thyroid Tissue
Lantz, M., Vondrichova, T., de Capretz, A., et al. (2007) · Thyroid · doi:10.1089/thy.2006.0155 · Cited by 8
Fadeev, V. V. (2020) · Clinical and experimental thyroidology · doi:10.14341/ket12474 · Cited by 9
Thyroid dermopathy and acropachy
Fatourechi, V. (2011) · Expert Review of Dermatology · doi:10.1586/edm.10.74 · Cited by 8
Kemchoknatee, P., Thongsawangchai, N., Srisombut, T., Tangon, D., & Chantra, S. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231199868 · Cited by 8
“15,36 In our series, although TSH levels were signi fi cantly lower in the DON group, these thyroid biochemistry factors could not be included in the logistic model for analyzing the risk of TED/DON because of multicollinearity.”
BackgroundOcular treatment of thyroid eye disease
Eichhorn, K., Harrison, A. R., Bothun, E. D., McLoon, L. K., & Lee, M. S. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.10.31 · Cited by 6
MANAGEMENT OF ENDOCRINE DISEASE: Predictive scores in autoimmune thyroid disease: are they useful?
Effraimidis, G. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0234 · Cited by 7
Endocrine ophthalmopathy and radioiodine therapy
Karlsson, F. A. (2006) · Acta Oncologica · doi:10.1080/02841860600760769 · Cited by 6
“[29] and the link between TSH receptor antibody levels and eye signs recently corroborated by Eckstein et al.”
BackgroundRadioiodine and thyroid-associated ophthalmopathy
Marcocci, C., Bartalena, L., Bogazzi, F., Bruno-Bossio, G., Tanda, M. L., Manetti, L., Dell'Unto, E., & Pinchera, A. (1996) · Orbit · doi:10.3109/01676839609150237 · Cited by 5
Clinical Presentation and Natural History of Graves’ Ophthalmopathy
Perros, P., Dickinson, A. J., & Kendall-Taylor, P. (2001) · Endocrine updates · doi:10.1007/978-1-4615-1447-3_8 · Cited by 5
Steroid Prophylaxis After Radioiodine Treatment for Graves' Hyperthyroidism: Selective or Universal?
Bartalena, L. (2014) · Thyroid · doi:10.1089/thy.2014.0349 · Cited by 5
“RAI is an effective and widely used form of treatment for Graves’ hyperthyroidism, but its use has been associated with a low, although not negligible risk of GO progression, especially in patients with preexisting GO, in smokers (4), and if post-RAI hypothyroidism is not promptly corrected (5).”
Zhang, H., Yang, L., Li, R., Bahn, R. S., Guan, H., & Zhou, H. (2026) · The EPMA Journal · doi:10.1007/s13167-026-00435-w · Cited by 8
“Table 1 Risk factors for the onset, progression and recurrence of thyroid eye disease (TED) and preventive actions thyroxine replacement therapy for post-radioiodine hypo-thyroidism has been shown to reduce TED risk by 57%, underscoring the critical importance of maintaining euthyroid status [115].”
Hiraiwa, T., Imagawa, A., Yamamoto, K., et al. (2009) · Endocrine · doi:10.1007/s12020-009-9177-z · Cited by 4
Thyroid Eye Disease: Pathogenic Risk Factors
Do, T. H., & Kahana, A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000355 · Cited by 4
Phowira, J., Coffey, K. L., Bartholomew, P. H., Vennart, N., Moreira, M., Emerson, H. M., Kennedy, D. W., & Weaver, J. U. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.843857 · Cited by 4
Genetic and Environmental Contributions to Pathogenesis
Wiersinga, W. M. (2001) · Endocrine updates · doi:10.1007/978-1-4615-1447-3_7 · Cited by 4
Lindholm, L. H., Sjölin, G., Jonsson, A., Abraham‐Nordling, M., Wallin, G., TT‐12 Study Group, & Nyström, H. F. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70034 · Cited by 3
“…our study, we have not included the cost for complications from surgery, such as hoarseness due to a laryngeal nerve palsy, hypocalcaemia due to permanent damage of the parathyroid glands [2], the cost for an increased frequency of Graves' orbitopathy after RAI [17, 26] or side effects of ATD [2].”
The evolution and hotspots of radioactive iodine therapy in hyperthyroidism: a bibliometric analysis
Chen, S., Gou, R.-Q., & Zhang, Q. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001940 · Cited by 3
Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys‐Waligórska, A., Gołkowski, F., Kuśnierz‐Cabala, B., Buziak‐Bereza, M., & Hubalewska–Dydejczyk, A. (2011) · PubMed · Cited by 3
Lind, P. (2001) · Acta Medica Austriaca · doi:10.1046/j.1563-2571.2001.01026.x · Cited by 3
Current Trends in the Management of Thyroid Ophthalmopathy
Kang, S., & Sa, H. (2016) · Hanyang Medical Reviews · doi:10.7599/hmr.2016.36.3.186 · Cited by 3
TSNM, Procedure Guideline for I-131 Treatment of Hyperthyroidism 2.0
Özdoğan, Ö., Töre, G., Özkılıç, H., Kır, M., & Yüksel, D. (2015) · Nuclear Medicine Seminars · doi:10.4274/nts.2015.009 · Cited by 3
Radioiodine Therapy and Graves’ Ophthalmopathy
Bartalena, L., Marcocci, C., & Pinchera, A. (2000) · Endocrine updates · doi:10.1007/978-1-4615-4407-4_20 · Cited by 3
Radioiodine and Gravesʼ ophthalmopathy reconsidered
Noury, A. M., Stanford, M. R., & GRAHAM, E. M. (2001) · Nuclear Medicine Communications · doi:10.1097/00006231-200111000-00001 · Cited by 3
Post-Radioiodine Graves' Management: The Pragma-Study
Perros, P., Dayan, C. M., Vaidya, B., Williams, G. R., Lazarus, J. H., Hickey, J., Willis, D., Archer, N., Franklyn, J. A., & Basu, A. (2016) · Endocrine Abstracts · doi:10.1530/endoabs.44.oc3.3 · Cited by 3
Jin, H., Yu, X., Cao, S., Wang, M., Hu, X., Ye, J., Liu, W., Xu, M., Wu, W., & Tu, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.990425 · Cited by 2
“Previous studies reported that uncontrolled hypothyroidism might contribute to the development and progression of TAO (Karlsson et al., 1989; Tallstedt et al., 1994; Perros et al., 2005).”
BackgroundBartalena, L., & Tanda, M. L. (2025) · Thyroid · doi:10.1089/thy.2025.0059 · Cited by 2
Gonzales, M., Fratianni, C. M., Mamillapali, C., & Khardori, R. K. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.013 · Cited by 2
Total Thyroidectomy in Treatment of Graves' Ophthalmopathy
Konturek, A. J., Barczyński, M., Cichoń, S., Anielski, R., Cichón, W., Jonkisz, J., & Orlicki, P. (2008) · Polish Journal of Surgery · doi:10.2478/v10035-008-0066-6 · Cited by 2
“close post-ablation monitoring of TSH levels (10, 11, 20, 21, 22).”
BackgroundPretibial Myxedema (Thyroid Dermopathy)
Fatourechi, V. (2008) · Springer eBooks · doi:10.1007/978-1-84800-187-9_10 · Cited by 2
McDermott, M., & Ridgway, E. C. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-5 · Cited by 2
Walasik‐Szemplińska, D., Kamiński, G., & Sudoł‐Szopińska, I. (2020) · Journal of Ultrasound in Medicine · doi:10.1002/jum.15401 · Cited by 2
“There is a positive correlation between the TRAb concentration and the severity of thyroid-associated orbitopathy, and the antibody titer may be a prognostic factor for de novo orbital changes after radioiodine treatment.(22) The effect of the TRAb concentration on the outcomes of radioiodine therapy has been debated…”
BackgroundRadioiodine Therapy for Benign Thyroid Disease
Clarke, S. E. (2008) · Springer eBooks · doi:10.1007/978-3-540-28026-2_21 · Cited by 2
The relationship between thyroid eye disease and radioiodine treatment
Thou, S., & Vinjamuri, S. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000965 · Cited by 2
Thyroid management in Graves’ ophthalmopathy
Prummel, M. F., Wiersinga, W. M., Marcocci, C., & Weetman, A. P. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4647-4_6 · Cited by 1
Combined Thyroid–Eye Clinics in the Management of Graves’ Ophthalmopathy
Wiersinga, W. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_14 · Cited by 1
“The occurrence of hypothyroidism after 131I therapy is an independent risk factor for GO worsening [ 3 ].”
BackgroundHollander, J. M., & Davies, T. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4745-2.00012-2 · Cited by 1
Schiffman, J. S., Sales‐Sanz, M., Rebolleda, G., Pass, A. F., Cruz, R. A., & Tang, R. A. (2013) · Expert Review of Ophthalmology · doi:10.1586/eop.13.4 · Cited by 1
Hyperthyroidism Due to Graves’ Disease, Toxic Nodules and Toxic Multinodular Goiter
Burman, K. D. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-3 · Cited by 1
Christina, E., Budiawan, H., Indrawati, H., et al. (2023) · PubMed · doi:10.22038/aojnmb.2023.68546.1478 · Cited by 1
Predictive factors for treatment response in active thyroid eye disease
Alkmim, N. R., Rajão, K. M. A. B., de Figueiredo, A. R. P., et al. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.09.001 · Cited by 1
Radioiodine Therapy of Graves’ Disease
Gross, M. D., Freitas, J. E., Sisson, J. C., & Shapiro, B. (2000) · Endocrine updates · doi:10.1007/978-1-4615-4407-4_11 · Cited by 1
Treatment Modalities in Thyroid Dysfunction
King, R., & Ajj, R. A. (2012) · InTech eBooks · doi:10.5772/38536 · Cited by 2
Novel ways to attack inflammation in thyroid eye disease
Chang, S.-H., & Douglas, R. S. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.10.35 · Cited by 1
Bartalena, L. (2019) · Springer eBooks · doi:10.1007/978-3-319-72102-6_23 · Cited by 1
Träisk, F. (2009) · Figshare · Cited by 1
Ninno, F. B. D., Esteres, R. Z., Marone, M. M. S., Dias-da-Silva, M. R., Matsumura, L. K., Hidal, J. T., Furlanetto, R. P., & Maciel, R. M. B. (1999) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27301999000200004 · Cited by 1
Hyperthyroidism : Incidence and long term quality-of-life
Abraham‐Nordling, M. (2008) · Figshare · Cited by 1
Radioiodine therapy and Gravesʼ ophthalmopathy
Bartalena, L. (2002) · Nuclear Medicine Communications · doi:10.1097/00006231-200211000-00016 · Cited by 1
New Strategies in the Control of Graves’ DiseasePreprint
Seo, S., Abalo-Lojo, J. M., & Vázquez-Lago, J. M. (2024) · Preprints.org · doi:10.20944/preprints202405.0001.v1
Gestione della disfunzione tiroidea nell’oftalmopatia basedowiana
Leo, M., Menconi, F., & Marinò, M. (2013) · L Endocrinologo · doi:10.1007/bf03346049
Radioiodine therapy for hyperthyroidism
Fard‐Esfahani, P., Beiki, D., Fallahi, B., Fard‐Esfahani, A., Emami-Ardekani, A., Ansari, M., & Eftekhari, M. (2011) · Iranian Journal of Nuclear Medicine
Bartalena, L., Baldeschi, L., Dickinson, A. J., Eckstein, A. K., Kendall‐Taylor, P., Marcocci, C., Mourits, M. P., Perros, P., Boboridis, K. G., Boschi, A., et al. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)72796-7
Therapy of Graves’ Ophthalmopathy
Wartofsky, L., Ringel, M. D., & Burman, K. D. (2000) · Endocrine updates · doi:10.1007/978-1-4615-4407-4_19
Graves’ Ophthalmopathy: A Comprehensive Role For Platelet-Derived Growth Factors
van Steensel, L. (2012)
Natural History, Risk Factors, and Management of Patients with Mild GO
Stan, M. N. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_18
“This approach was tested earlier by Tallstedt and his colleagues [ 31 ] when they compared a cohort of patients treated with levothyroxine only when hypothyroidism developed (approximately 3 months after RAI therapy) and compared it with a group of patients that received LT4 as early as 2 weeks after RAI, at a dose of…”
ResultBest Practice & Research Clinical Endocrinology & Metabolism
der Grinten, H. L. C., Otten, B. J., Stikkelbroeck, M., Sweep, F. C. G. J., & Hermus, A. R. M. M. (2009)
The Risk of Orbital Disease Following Radioactive Iodine Treatment
Tallstedt, L. (2002) · CRC Press eBooks · doi:10.3109/9780203908983-26
Self-citationBartalena, L. (2018) · Endocrinology · doi:10.1007/978-3-319-45013-1_17
General Management Plan for Graves' Orbitopathy
Bartalena, L. (2017) · KARGER eBooks · doi:10.1159/000475952
Taïeb, D. (2020) · Médecine Nucléaire · doi:10.1016/j.mednuc.2020.06.003
Pathogenesis and Medical Management of Thyroid Eye Disease
Carniciu, A. L., & Kahana, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-41720-8_57
Pratipanawat, P. (2019) · Srinagarind Medical Journal-ศรีนครินทร์เวชสาร
Graves’ ophthalmopathy and dermopathy
Wiersinga, W. M. (2011) · doi:10.1093/med/9780199235292.003.3205
Bartalena, L. (2016) · Endocrinology · doi:10.1007/978-3-319-29195-6_17-1
Feldkamp, J., & Scherbaum, W. A. (2001) · Springer eBooks · doi:10.1007/978-3-642-56784-1_4
Uslu, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-78476-2_6
Cooper, D. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-277-7_4
Management of Thyroid Dysfunction in People with TED
Rao-Waronski, V., & Vaidya, B. (2025) · Springer eBooks · doi:10.1007/978-3-031-99672-6_14
Treatment of Hyperthyroidism in Patients with Graves’ Orbitopathy
Bartalena, L. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_16
Metadata
- Authors
- Tallstedt, L., Lundell, G., Blomgren, H., & Bring, J.
- Affiliations
- Karolinska University Hospital (SE)
- Uppsala University (SE)
- Corresponding author
- Tallstedt, Leif
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-05
- Volume
- 130
- Issue
- 5
- Pages
- 494-497
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2153640804
- Cited by
- 171
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 8 · 2018: 4 · 2017: 1 · 2016: 11 · 2015: 7 · 2014: 6 · 2013: 8 · 2012: 13
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' ophthalmopathy, thyroxine, radioiodine therapy, iodine-131, Graves' disease, hyperthyroidism, thyroid hormones, proptosis, prophylaxis, hypothyroidism
- MeSH terms
- Drug Administration Schedule, Exophthalmos, Female, Graves Disease, Humans, Hyperthyroidism, Iodine Radioisotopes, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Thyroxine, Time Factors, Confidence Intervals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
